New pathways that control inflammation-linked fatty molecules
Novel pathways in eicosanoid biosynthesis and metabolism
Learning how the body makes and changes inflammation-related fatty molecules and how common drugs like aspirin alter them, which matters to people who take NSAIDs or have inflammatory conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11141061 on NIH RePORTER |
What this research studies
This project looks at how enzymes in the body create and modify eicosanoids, a family of fat-based signaling molecules tied to inflammation and health. Researchers use biochemical experiments and lipidomics (detailed molecule profiling) to discover new eicosanoids and the enzyme steps that create them, including aspirin-driven changes. They also study how these molecules are further metabolized and whether plasma or urine breakdown products can serve as markers of drug response. The work aims to connect these chemical pathways to how NSAIDs affect the body and to improve interpretation of blood and urine tests.
Who could benefit from this research
Good fit: Ideal participants would be people who regularly take aspirin or other NSAIDs, or patients with inflammatory conditions willing to provide blood or urine samples.
Not a fit: People who never use NSAIDs and have no inflammatory condition are unlikely to gain direct benefit from this work.
Why it matters
Potential benefit: If successful, this work could lead to better tests to show who will respond to NSAIDs and help guide safer use of drugs like aspirin.
How similar studies have performed: Previous lipidomics and biochemical studies have identified aspirin-altered prostaglandins and other novel eicosanoids, so parts of this approach have succeeded before while some pathways remain newly discovered.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Schneider, Claus — Vanderbilt University
- Study coordinator: Schneider, Claus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.